Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies  Frank C. Albers, MD, PhD, Robert G. Price,

Published byCecilia Falk Modified over 4 years ago

Similar presentations

Presentation on theme: "Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies  Frank C. Albers, MD, PhD, Robert G. Price,"— Presentation transcript:

1 Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies  Frank C. Albers, MD, PhD, Robert G. Price, MSc, Steven G. Smith, PhD, Steven W. Yancey, MSc  Journal of Allergy and Clinical Immunology  Volume 140, Issue 5, Pages e4 (November 2017) DOI: /j.jaci Copyright © 2017 GSK Terms and Conditions

2 Fig 1 Reductions in exacerbation rate according to the number of standard of care asthma controller therapies taken in addition to mepolizumab or placebo. RR, Rate ratio. 95% CIs shown in parentheses after RR; number of patients presented at the bottom of each bar. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2017 GSK Terms and Conditions

3 Fig 2 Reductions in exacerbation rate according to the type of standard of care asthma controller therapies taken in addition to mepolizumab or placebo. RR, Rate ratio; TIO, tiotropium. 95% CIs shown in parentheses after RR; number of patients presented at the bottom of each bar; other could be 1 or more of leukotriene receptor antagonists, xanthine, or nedocromil/cromolyn sodium; 5 patients did not report a LABA controller and therefore are not included in Fig 2. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2017 GSK Terms and Conditions

4 Fig E1 Reductions in exacerbation rate according to the number of standard of care asthma controller therapies taken in addition to 100 mg SC mepolizumab or placebo. RR, Rate ratio. Reductions presented as RR (95% CI); patient numbers are presented at the bottom of each bar. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2017 GSK Terms and Conditions

5 Fig E2 Reductions in exacerbation rate according to the type of standard of care asthma controller therapies taken in addition to 100 mg SC mepolizumab or placebo. RR, Rate ratio; TIO, tiotropium. Reductions presented as RR (95% CI); patient numbers are presented at the bottom of each bar; other could be 1 or more of leukotriene receptor antagonists, xanthine, or nedocromil/cromolyn sodium; 5 patients did not report a LABA controller and, therefore, are not included in Fig E2. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2017 GSK Terms and Conditions

Download ppt "Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies  Frank C. Albers, MD, PhD, Robert G. Price,"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,
Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,
Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,

Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity  Andrei Malinovschi,
Jonathan Malka, MD, David T

Jonathan Malka, MD, David T
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma  Erik B. Hysinger, MD, Jeffrey D. Roizen,

Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma  Erik B. Hysinger, MD, Jeffrey D. Roizen,
Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy 

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy 
Practice Notes from the AAAI

Practice Notes from the AAAI
Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012  Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012  Anni Nørgaard Jeppesen, MD, Christian Fynbo.
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis  Philippe Gevaert, MD, PhD, Nicholas Van Bruaene, MD, Tom Cattaert,

Similar presentations

Ads by Google